Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Asenapine, Olanzapine Effective in Patients With Bipolar 1 Disorder: Presented at WCBP - (DGDispatch)
    FDA: Boxed Warning Required for Varenicline, Buproprion Due to Risk of Suicidal Behaviour - (DGNews)
    Quetiapine Monotherapy Shows Potential in Post-Traumatic Stress Disorder: Presented at WCBP - (DGDispatch)
    Olanzapine Effective for Bipolar Disorder in Naturalistic Setting: Presented at WCBP - (DGDispatch)
    Study Suggests Irritability Should Be Considered When Diagnosing Bipolar Disorder in Children - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
      A Guide to Advances in Pain Management: A Synopsis of Roundtable Discussions
      Recognizing and Managing Psychotic and Mood Disorders in Primary Care
      Challenges of the Comorbid Patient: Evaluating Common Comorbidities in Adults and Children/Adolescents and Treatment Considerations
      Mixed States: Practical Application of Evidence, Guidelines, and Clinical Judgment
      Hypomania: The Clinical Reality of Diagnosing Adult and Child/Adolescent Patients

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Female Sexual Dysfunction as a Comorbid Illness
        11p Microdeletion Including WT1 but not PAX6, Presenting with Cataract, Mental Retardation, Genital Abnormalities and Seizures: Case Report
        Comorbidity of Asperger's Syndrome and Bipolar Disorder
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Adults with ADHD Respond Well to Once-Daily Multilayer-Release Formulation of Methylphenidate (Biphentin): Presented at AACAP

        By Paula Moyer

        TORONTO, CANADA -- October 31, 2005 -- Adults with attention deficit hyperactivity disorder (ADHD) respond well to a multilayer-release formulation of methylphenidate (Biphentin), according to investigators who presented findings here at the joint meeting of the American and Canadian Academies of Child and Adolescent Society (AACAP/CACAP).

        "This formulation of methylphenidate produced significant improvement in ADHD symptoms and behavior for adults at home and at work or school," according to presenter Graeme Donnelly, MS, Clinical Research Scientist, Purdue Pharma, Pickering, Ontario, Canada, which manufactures Biphentin.

        Dr. Donnelly noted that several study participants were university students. "This formulation may expand treatment options for adults with ADHD because of its convenience and tolerability, as well as its efficacy."

        The investigators wanted to address a key therapeutic concern of adults with ADHD, who often express a desire for a treatment with a rapid onset of action, as with immediate-release methylphenidate (Ritalin), but yet a long duration of action so that patients can fulfill their responsibilities at work and at home.

        In the randomized, double-blind, crossover trial, patients received no medication during the first week of the trial, after which they received a titrated dosage of methylphenidate multilayer release formulation for 1 to 3 weeks. After a maximal effect of the medication was achieved, patients received a stable dose of treatment for 2 weeks.

        Among the original 50 patients, 39 completed the study, consisting of 23 men and 16 women who were an average of 37.9 years old. The investigators rated the effect of treatment with the Clinical Global Impressions (CGI) scale and the Connors Adult ADHD Rating Scales (CAARS-Self and CAARS-Observer), which they conducted at weekly visits.

        Treatment with Biphentin significantly improved symptoms compared to placebo, as seen by CGI scores of 2.6 and 3.7, respectively (P = .0015). The improvement over baseline on the ADHD index on the CAARS-S was 12.2 points in the treatment group compared to 5.4 in the placebo group (P = .0083). The change on the same index on the CAARS-O trended to significance, a change of 10.9 in the treatment group compared to 6.8 in the placebo group (P = .14).

        The most frequent adverse events were headache (26% and 24%), and anorexia (22% and 6%). Other adverse events included insomnia (20% and 4%), nervousness (20% and 4%), and nausea (16% and 8%). No serious adverse events occurred, the investigators reported.

        Purdue Pharma sponsored the study.


        [Presentation title: Double-blind, Placebo-Controlled, Crossover Study of Multiplayer-Release Methylphenidate in Adult ADHD. Abstract C-19]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send